Aderbasib-d3

Aderbasib-d3 (INCB007839-d3) is deuterium labeled Aderbasib. Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2+?breast cancer, gliomas, et al[1].

Product Specifications

Product Name Alternative

INCB007839-d3; INCB7839-d3

UNSPSC

12352005

Target

Isotope-Labeled Compounds; MMP

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(N([C@@H]1C(N2CCN(CC2)C3=CC=CC=C3)=O)CC4(C[C@@H]1C(NO)=O)CC4)OC([2H])([2H])[2H]

Molecular Formula

C21H25D3N4O5

Molecular Weight

419.49

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Lois Witters, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008 Sep 1;68 (17) :7083-9.|[3]Fei Yuan, et al. ADAM17 is an essential attachment factor for classical swine fever virus. PLoS Pathog. 2021 Mar 8;17 (3) :e1009393.